123 related articles for article (PubMed ID: 31691633)
1. Selection of the optimal personalized treatment from multiple treatments with multivariate outcome measures.
Siriwardhana C; Datta S; Kulasekera KB
J Biopharm Stat; 2020 May; 30(3):462-480. PubMed ID: 31691633
[TBL] [Abstract][Full Text] [Related]
2. Optimal Personalized Treatment Selection with Multivariate Outcome Measures in a Multiple Treatment Case.
Siriwardhana C; Kulasekera KB
Commun Stat Simul Comput; 2023; 52(12):5773-5787. PubMed ID: 38371330
[TBL] [Abstract][Full Text] [Related]
3. Quantiles based personalized treatment selection for multivariate outcomes and multiple treatments.
Kulasekera KB; Siriwardhana C
Stat Med; 2022 Jul; 41(15):2695-2710. PubMed ID: 35699385
[TBL] [Abstract][Full Text] [Related]
4. Multi-Response Based Personalized Treatment Selection with Data from Crossover Designs for Multiple Treatments.
Kulasekera KB; Siriwardhana C
Commun Stat Simul Comput; 2022; 51(2):554-569. PubMed ID: 35299995
[TBL] [Abstract][Full Text] [Related]
5. Personalized treatment selection using data from crossover designs with carry-over effects.
Siriwardhana C; Kulasekera KB; Datta S
Stat Med; 2019 Dec; 38(28):5391-5412. PubMed ID: 31637762
[TBL] [Abstract][Full Text] [Related]
6. Selection of the optimal personalized treatment from multiple treatments with right-censored multivariate outcome measures.
Siriwardhana C; Kulasekera KB; Datta S
J Appl Stat; 2024; 51(5):891-912. PubMed ID: 38524800
[TBL] [Abstract][Full Text] [Related]
7. A probability based method for selecting the optimal personalized treatment from multiple treatments.
Siriwardhana C; Zhao M; Datta S; Kulasekera KB
Stat Methods Med Res; 2019 Mar; 28(3):749-760. PubMed ID: 29145777
[TBL] [Abstract][Full Text] [Related]
8. Personalized treatment plans with multivariate outcomes.
Siriwardhana C; Kulasekera KB
Biom J; 2020 Dec; 62(8):1973-1985. PubMed ID: 32627863
[TBL] [Abstract][Full Text] [Related]
9. Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
Stühler E; Braune S; Lionetto F; Heer Y; Jules E; Westermann C; Bergmann A; van Hövell P;
BMC Med Res Methodol; 2020 Feb; 20(1):24. PubMed ID: 32028898
[TBL] [Abstract][Full Text] [Related]
10. Identifying treatment responders using counterfactual modeling and potential outcomes.
Porcher R; Jacot J; Wunder JS; Biau DJ
Stat Methods Med Res; 2019; 28(10-11):3346-3362. PubMed ID: 30298794
[TBL] [Abstract][Full Text] [Related]
11. Estimating the Optimal Personalized Treatment Strategy Based on Selected Variables to Prolong Survival via Random Survival Forest with Weighted Bootstrap.
Shen J; Wang L; Daignault S; Spratt DE; Morgan TM; Taylor JMG
J Biopharm Stat; 2018; 28(2):362-381. PubMed ID: 28934002
[TBL] [Abstract][Full Text] [Related]
12. A conditional error function approach for subgroup selection in adaptive clinical trials.
Friede T; Parsons N; Stallard N
Stat Med; 2012 Dec; 31(30):4309-20. PubMed ID: 22865774
[TBL] [Abstract][Full Text] [Related]
13. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
Wang X; Zhou J; Wang T; George SL
J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
[TBL] [Abstract][Full Text] [Related]
14. A class of Covariate-Adjusted Response-Adaptive Allocation Designs for Multitreatment Binary Response Trials.
Biswas A; Bhattacharya R
J Biopharm Stat; 2018; 28(5):809-823. PubMed ID: 29913107
[TBL] [Abstract][Full Text] [Related]
15. Analysis of randomized comparative clinical trial data for personalized treatment selections.
Cai T; Tian L; Wong PH; Wei LJ
Biostatistics; 2011 Apr; 12(2):270-82. PubMed ID: 20876663
[TBL] [Abstract][Full Text] [Related]
16. Enhanced precision in the analysis of randomized trials with ordinal outcomes.
Díaz I; Colantuoni E; Rosenblum M
Biometrics; 2016 Jun; 72(2):422-31. PubMed ID: 26576013
[TBL] [Abstract][Full Text] [Related]
17. Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data.
Foster JC; Taylor JM; Kaciroti N; Nan B
Biostatistics; 2015 Apr; 16(2):368-82. PubMed ID: 25398774
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous evaluation of the harms and benefits of treatments in randomized clinical trials: demonstration of a new approach.
Frank E; Kupfer DJ; Rucci P; Lotz-Wallace M; Levenson J; Fournier J; Kraemer HC
Psychol Med; 2012 Apr; 42(4):865-73. PubMed ID: 21861951
[TBL] [Abstract][Full Text] [Related]
19. Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy.
Laber EB; Zhao YQ; Regh T; Davidian M; Tsiatis A; Stanford JB; Zeng D; Song R; Kosorok MR
Stat Med; 2016 Apr; 35(8):1245-56. PubMed ID: 26506890
[TBL] [Abstract][Full Text] [Related]
20. Timing of the interim analysis in adaptive enrichment designs.
Benner L; Kieser M
J Biopharm Stat; 2018; 28(4):622-632. PubMed ID: 29064745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
